MARAVAI LIFESCIENCES HOLDINGS, INC. Maravai LifeSciences Holdings, Inc. Stock
Equities
MRVI
US56600D1072
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.67 USD | -2.47% |
|
-20.09% | +32.37% |
Financials (USD)
| Sales 2024 * | 275M | Sales 2025 * | 303M | Capitalization | 1.15B |
|---|---|---|---|---|---|
| Net income 2024 * | -32M | Net income 2025 * | -8M | EV / Sales 2024 * | 3.91 x |
| Net cash position 2024 * | 73.18M | Net cash position 2025 * | 128M | EV / Sales 2025 * | 3.38 x |
| P/E ratio 2024 * |
-39.9
x | P/E ratio 2025 * |
-81.8
x | Employees | 570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Maravai LifeSciences Holdings, Inc.
More recommendations
More press releases
More news
| 1 day | -2.47% | ||
| 1 week | -20.09% | ||
| 1 month | +2.97% | ||
| 3 months | +14.23% | ||
| 6 months | +61.45% | ||
| Current year | +32.37% |
1 week
8.59
11.16
1 month
8.5911.56
Current year
5.0511.56
1 year
4.5214.88
3 years
4.5263.55
5 years
4.5263.55
10 years
4.5263.55
| Managers | Title | Age | Since |
|---|---|---|---|
William Martin
CEO | Chief Executive Officer | 49 | 22-09-29 |
Carl Hull
FOU | Founder | 66 | 14-02-28 |
Kevin Herde
DFI | Director of Finance/CFO | 53 | 17-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dean Mihas
BRD | Director/Board Member | 57 | 16-02-29 |
Sean Cunningham
BRD | Director/Board Member | 48 | 16-02-29 |
Gregory Lucier
BRD | Director/Board Member | 59 | 19-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.50% | 12 M€ | -.--% | - | |
| 0.37% | 8 M€ | -.--% | ||
| 0.34% | 2 M€ | -.--% | ||
| 0.28% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 8.67 | -2.47% | 2,174,305 |
| 24-05-30 | 8.89 | -0.45% | 2,060,572 |
| 24-05-29 | 8.93 | -17.16% | 4,399,095 |
| 24-05-28 | 10.78 | -0.65% | 1,014,778 |
| 24-05-24 | 10.85 | +0.65% | 1,135,583 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
8.67
USD
Average target price
10.42
USD
Spread / Average Target
+20.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.37% | 1.15B | |
| -38.56% | 8.39B | |
| +0.18% | 3.32B | |
| +9.29% | 2.48B | |
| -18.21% | 2.06B | |
| -24.57% | 1.59B | |
| -7.64% | 704M | |
| +8.42% | 678M | |
| -29.59% | 508M | |
| -6.56% | 273M |
- Stock Market
- Equities
- MRVI Stock
